Atherothrombosis

Discover more on science updates, events, KOLs interviews and more on Atherothrombosis

Science in Atherothrombosis

Get a 360º view and stay up-to-date on Atherothrombosis with content selected for you

See everything

Atherothrombosis
Cardiovascular
Atherothrombosis

No Rebound Effect Post Clopidogrel Withdrawal

Learn More

Atherothrombosis

Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice

Learn More

Atherothrombosis

Ticagrelor vs Clopidogrel in Older Patients With ACS PCI

Learn More

Atherothrombosis

Ticagrelor vs Clopidogrel in high bleeding risk patients with ACS

Learn More

Atherothrombosis

In hospital outcomes in young patients with AMI: Results from Gulf Coast

Learn More

Atherothrombosis

Adherence and persistence analysis in patients treated with DAPT

Learn More

Atherothrombosis

Effect of de-escalated P2Y12 inhibitor switching in dual antiplatelet therapy (DAPT)

Learn More

Atherothrombosis

Is Clopidogrel a viable first choice P2Y12 inhibitor for DAPT after PCI?

Learn More

See everything

Inspiration and innovation

Get inspired and stay at the forefront of innovation with the following resources

See everything

Atherothrombosis
Cardiovascular
Atherothrombosis

No Rebound Effect Post Clopidogrel Withdrawal

Learn More

Atherothrombosis
Atherothrombosis

DAPT in Elderly with CAD Meta Analysis

Watch the video and get to know more on the crucial insights from this systematic review and meta-analysis of DAPT in elderly patients with acute coronary syndrome (ACS). Dual oral antiplatelet therapy (DAPT) with prasugrel or ticagrelor is associated with a higher risk of bleeding events in elderly patients with ACS compared to clopidogrel, with no difference in primary efficacy endpoint rates between the treatment groups.

Learn More